A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort

Scientific Reports, Journal Year: 2018, Volume and Issue: 8(1)

Published: Feb. 21, 2018

Abstract Global gene expression analysis has been a major tool for urothelial carcinoma subtype discovery. This approach revealed extensive complexity both in intrinsic features of the tumor cells and microenvironment. However, global cannot distinguish between signals originating from proper normal biopsy. Here, we use large cohort advanced carcinomas which data immunohistochemistry are available to create supervised mRNA centroid classifier. classifier identifies Lund taxonomy cell phenotypes as defined by IHC. We apply this independent TCGA dataset show excellent associations identified subtypes genomic features. validate progressed version Urothelial-like A (UroA-Prog) that shows FGFR3 mutations CDKN2A deletions, variant C is almost devoid mutations. Genomically Unstable tumors very distinct at level, classified Basal/SCC-like all complied with established definition tumors. identify Mesenchymal-like Small-cell/Neuroendocrine-like subtypes, demonstrate patients UroB Sc/NE-like worst overall survival.

Language: Английский

---

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

Annals of Oncology, Journal Year: 2018, Volume and Issue: 29(3), P. 563 - 572

Published: Jan. 6, 2018

The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC focus virology research for over decade. Many lessons learnt regarding within are likely to be applicable cancer. this review, we explore the parallels between role enzymes HIV and cancer evolution. We discuss data supporting mutagenesis creating genome heterogeneity, drug resistance, immune escape variants. hypothesize similar functions will also hold true

Language: Английский

---

Molecular Subtypes of Bladder Cancer

Current Oncology Reports, Journal Year: 2018, Volume and Issue: 20(10)

Published: Aug. 20, 2018

Language: Английский

---

Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas

JNCI Journal of the National Cancer Institute, Journal Year: 2018, Volume and Issue: 110(5), P. 448 - 459

Published: Jan. 3, 2018

Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of prognostic tool can guide decision-making crucial improving management urothelial carcinomas.

Language: Английский

---

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review

European Urology, Journal Year: 2018, Volume and Issue: 73(5), P. 738 - 748

Published: April 11, 2018

Language: Английский

---